Vertex Pharmaceuticals (VRTX) Other Working Capital Changes (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Other Working Capital Changes of -$173.4 million for Q1 2026, down 717.08% year-over-year from $28.1 million in Q1 2025, and down 169.19% quarter-over-quarter from $250.6 million in Q4 2025.
Vertex Pharmaceuticals (VRTX) Other Working Capital Changes (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Other Working Capital Changes history runs 18 years deep, the most recent figure standing at -$173.4 million for Q1 2026.
- In Q1 2019, Other Working Capital Changes fell 8.07% year-over-year to $35.7 million; the TTM figure through Mar 2019 stood at $74.5 million (changed N/A YoY), while the FY2018 annual figure was $129.3 million, down 18.69% from the prior year.
- Other Working Capital Changes for Q1 2019 stood at $35.7 million, down from $38.8 million in the prior quarter.
- The five-year high for Other Working Capital Changes was $38.8 million in Q1 2018, with the low at $35.7 million in Q1 2019.
- The 5-year median for Other Working Capital Changes is $40.9 million (2025), against an average of $76.2 million.
- The sharpest annual moves came in 2022 and 2026: Other Working Capital Changes soared 1889.31% in 2022, then tumbled 717.08% in 2026.
- Vertex Pharmaceuticals' Other Working Capital Changes stood at $38.8 million in 2018, then decreased by 8.07% to $35.7 million in 2019.
- Business Quant data shows VRTX's Other Working Capital Changes at $35.7 million in Q1 2019, $38.8 million in Q1 2018, and -$204000.0 in Q1 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 51.40 Mn |
| Jun 30, 2026 | 51.40 Mn |
| Jun 30, 2026 | 51.40 Mn |
| Mar 31, 2026 | -173.40 Mn |
| Mar 31, 2026 | -173.40 Mn |
| Mar 31, 2026 | -173.40 Mn |
| Dec 31, 2025 | 250.60 Mn |
| Dec 31, 2025 | 250.60 Mn |
| Dec 31, 2025 | 250.60 Mn |
| Sep 30, 2025 | 40.90 Mn |
| Sep 30, 2025 | 40.90 Mn |
| Sep 30, 2025 | 40.90 Mn |
| Jun 30, 2025 | 76.40 Mn |
| Jun 30, 2025 | 76.40 Mn |
| Jun 30, 2025 | 76.40 Mn |
| Mar 31, 2025 | 28.10 Mn |
| Mar 31, 2025 | 28.10 Mn |
| Mar 31, 2025 | 28.10 Mn |
| Dec 31, 2024 | 164.60 Mn |
| Dec 31, 2024 | 164.60 Mn |